Refine by
Dna Free Articles & Analysis
6 news found
The testing works by isolating cell-free DNA (cfDNA) from blood plasma to uncover circulating tumor DNA (ctDNA). Isolating these DNA samples from a simple blood draw is less invasive than a traditional biopsy, helping to simplify patient monitoring and more quickly guide clinical decision-making. ...
Using our molecular counting technology, the assay provides absolute quantification of methylated circulating tumor DNA (ctDNA) burden. The purpose of the assay, when it becomes clinically available in Q1 2023, will be to enable clinicians to monitor patients’ responses to therapies, including in late-stage cancers for which minimal residual disease (MRD) assays may not be ...
The company leverages proprietary, state-of-the-art computational biology tools combined with targeted next generation sequencing (NGS) assay platform for highly sensitive cancer signal scoring of cell-free DNA regions linked to cancer of interest. The company is developing "Signal-X", a platform to detect multiple types of cancer; its first product, "Signal-C", ...
UNITY improves clinical specificity for cystic fibrosis carrier screening UNITY is the only prenatal screen that tests cell-free fetal DNA for cystic fibrosis, spinal muscular atrophy (SMA), sickle cell disease, and alpha and beta thalassemia using just one tube of blood from the mother. ...
A non-invasive prenatal test for Alpha Thalassemia Hb Barts and Hb Constant Spring UNITY is the only prenatal screen that tests cell-free fetal DNA for cystic fibrosis, spinal muscular atrophy (SMA), sickle cell disease, and alpha and beta thalassemia using just one tube of blood from the mother. ...
Her presentation will highlight case study data derived from Thermo Fisher's cell-free DNA assay; while Prof. Dr. José Luis Rodríguez Peralto, Ph.D., M.D., Head of the Pathology department, Hospital 12 de Octubre, Madrid, will discuss the advantages of bringing NGS into a pathology laboratory. ...